No it doesn't. Both dosings use two shots, and the "90%" number from the smaller dosing is from an unreliably small sample set of 33 infections -- it could easily be 70-80% by next month when more data comes in.
Can you count infections as a metric of efficacy for a vaccine that's designed to stop infection?
Consider [1]:
"However, protection was 90% in an analysis of around 3,000 people on the trial who were given a half-sized first dose and a full-sized second dose."
AFAIK it's not known how many of those 3,000 in that trial were exposed to potential infection.
The bars are to be calculated using conditional probabilities.